Jenna Haverfield

Jenna Haverfield

Auto-generated profile, based on publicly available information

Jenna Haverfield

Research Institute of the McGill University Health Centre , Montréal, QC

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
HWHolly O. Witteman
Holly O. Witteman
JHJenna Haverfield
Jenna Haverfield
CTCara Tannenbaum
Cara Tannenbaum
The COVID-19 pandemic has exposed and exacerbated gender biases in science, technology, engineering, mathematics, and medicine. Accumulating evidence suggests that female scientists’ productivity dropped during the initial lockdown period. With more time being spent on caregiving responsibilities, women may be struggling to collaborate on grant applications and launch new experiments. Scientists with disabilities or who belong to Indigenous nations or communities of color may have less time to devote to research due to health, family, or community needs. Collateral damage in this situation, the appropriate integration of sex, gender, and other identity characteristics in research content may also suffer. Sex and gender are better attended to when female scientists form part of the research team. Research funding agencies have a role to play in mitigating these effects by putting in place gender equity policies that support all applicants and ensure research quality. Accordingly, a national health research funder implemented gender policy changes that included extending deadlines and factoring sex and gender into COVID-19 grant requirements. Following these changes, the funder received more applications from female scientists, awarded a greater proportion of grants to female compared to male scientists, and received and funded more grant applications that considered sex and gender in the content of COVID-19 research. Whether or not these strategies will be sufficient in the long-term to prevent widening of the gender gap in science, technology, engineering, mathematics and medicine requires continued monitoring and oversight. Further work is urgently required to mitigate inequities associated with identity characteristics beyond gender.

16 July 2026 in Clinical Kidney Journal
Verified
Journal Article
Open access
ILIris Y Liu
Iris Y Liu
JHJenna Haverfield
Jenna Haverfield
EMElby MacKenzie
Elby MacKenzie
LDLine Dufresne
Line Dufresne
ARAimee K. Ryan
Aimee K. Ryan
IGIndra Gupta
Indra Gupta
Background: The tight junction family of claudin proteins regulates paracellular ion transport in the nephron and across epithelial and endothelial barriers throughout the body. Rare recessive variants in CLDN16 and CLDN19 cause familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), while common variants in CLDN2, CLDN10, and CLDN14 have been associated with kidney stones. Despite evidence that most claudin proteins are expressed within the nephron, their genetic contribution to kidney stone susceptibility has not been systematically explored. Methods: We analyzed 415 237 UK Biobank participants (9009 kidney stone cases and 406 228 controls) using exome sequencing and imputed genotype data spanning all 24 human CLDN genes. Single-variant association testing, gene burden analysis, and phenome-wide association studies were employed to identify novel associations. Results: Forty-three novel coding variant associations were identified through exome sequencing, including two CLDN16 variants: p.Gly57Arg (rs747654138; odds ratio [OR] = 42.2, P = 9.5 × 10−8) and p.Arg146His (rs772241737; OR = 60.5, P = 8.1 × 10−4). We replicated a known association with a CLDN19 variant, p.Arg200Gln (rs116804195; OR = 1.23, P = 2.6 × 10−4), which was also associated with decreased serum phosphate and increased alkaline phosphatase. We also identified 13 novel susceptibility loci within the imputed genotype dataset, including single nucleotide polymorphisms near CLDN2, CLDN10, CLDN11, CLDN18, and CLDN22–CLDN24 (all P < 0.00025), and confirmed a known CLDN14 association. Conclusions: Beyond established FHHNC genes, multiple CLDN family members harbor variants potentially influencing kidney stone risk, possibly through altered paracellular transport and mineral homeostasis. These findings expand kidney stone genetic architecture and suggest that claudin proteins merit further investigation in its pathogenesis.

7 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CACarlos Agustin Isidro Alonso
Carlos Agustin Isidro Alonso
JHJenna Haverfield
Jenna Haverfield
GRGabriela Regalado
Gabriela Regalado
SSSihem Sellami
Sihem Sellami
NGNatascha Gagnon
Natascha Gagnon
IGIndra Gupta
Indra Gupta
Background: Arsenic is a naturally occurring toxicant and industrial byproduct with significant health risks. Globally, millions of people are exposed to arsenic concentrations that exceed the World Health Organization’s recommended limit of 10 μg/L. Chronic arsenic exposure is linked to an increased risk of chronic kidney disease (CKD); however, the effects of arsenic exposure on kidney development remain unclear. Eukaryotes methylate inorganic arsenic (iAsIII) using the enzyme arsenic 3 methyltransferase (As3mt), that converts it to methylated intermediates, mono and dimethyl arsonous acid (MMAIII and DMAIII), and mono and dimethyl arsonic acid (MMAV and DMAV). We hypothesized that arsenicals exposure during mouse kidney development impairs nephron formation. Methods: Cultured mouse embryonic kidney explants were treated with inorganic arsenite (iAsIII), MMAIII, MMAV, and DMAV. Female mice harboring a humanized version of AS3MT and wild-type mice with murine As3mt were exposed to iAsIII throughout gestation and weaning and their offspring were analyzed for kidney defects. Results: Inorganic arsenic, iAsIII (200 μg/L), inhibited ureteric bud branching morphogenesis and growth of mouse kidneys at embryonic day 11.5 (E11.5) and E12.5, but not at E13.5. MMAIII, but not MMAV or DMAV, impaired ureteric bud branching and kidney explant growth. Additionally, iAsIII exposure increased apoptosis in the metanephric mesenchyme of E11.5 explants and decreased Gdnf transcription, which may explain the impairment in ureteric bud branching. Humanized mouse pups exposed to 200 μg/L iAsIII in utero , showed a 20% reduction in kidney weight normalized to body weight and a 28% reduction in nephron number, compared to kidneys of wild-type mice. Conclusion: Exposure to arsenicals during embryonic development impairs ureteric bud branching morphogenesis and decreases nephron endowment, which may predispose to CKD in adulthood.